These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 24833294)

  • 1. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
    Cook D; Brown D; Alexander R; March R; Morgan P; Satterthwaite G; Pangalos MN
    Nat Rev Drug Discov; 2014 Jun; 13(6):419-31. PubMed ID: 24833294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a five-dimensional framework on R&D productivity at AstraZeneca.
    Morgan P; Brown DG; Lennard S; Anderton MJ; Barrett JC; Eriksson U; Fidock M; Hamrén B; Johnson A; March RE; Matcham J; Mettetal J; Nicholls DJ; Platz S; Rees S; Snowden MA; Pangalos MN
    Nat Rev Drug Discov; 2018 Mar; 17(3):167-181. PubMed ID: 29348681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extinction of drugs for clinical research: Can the ECNP medicines chest save them?
    Nutt D; Kilpatrick G; Hayes A
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):487-90. PubMed ID: 24508534
    [No Abstract]   [Full Text] [Related]  

  • 4. Lessons learned from candidate drug attrition.
    Empfield JR; Leeson PD
    IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An assessment of R&D productivity in the pharmaceutical industry.
    Dimitri N
    Trends Pharmacol Sci; 2011 Dec; 32(12):683-5. PubMed ID: 22030299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
    Cockburn IM; Henderson RM
    J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Algorithmic benchmark modulation: A novel method to develop success rates for clinical studies.
    Willigers BJ; Nagarajan S; Ghiorghui S; Darken P; Lennard S
    Clin Trials; 2024 Apr; 21(2):220-232. PubMed ID: 38126256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of drug metabolism and pharmacokinetics for new drug development.
    Kim YG; Kang KW
    Arch Pharm Res; 2011 Nov; 34(11):1769-71. PubMed ID: 22139678
    [No Abstract]   [Full Text] [Related]  

  • 9. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The right compound in the right assay at the right time: an integrated discovery DMPK strategy.
    Ballard P; Brassil P; Bui KH; Dolgos H; Petersson C; Tunek A; Webborn PJ
    Drug Metab Rev; 2012 Aug; 44(3):224-52. PubMed ID: 22697420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing attrition in drug development: smart loading preclinical safety assessment.
    Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
    Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Torching the Haystack: modelling fast-fail strategies in drug development.
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmaceutical industry and research in 2002 and beyond.
    Dutta AS; Garner A
    Drug News Perspect; 2003 Dec; 16(10):637-48. PubMed ID: 14747843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novelty in the target landscape of the pharmaceutical industry.
    Agarwal P; Sanseau P; Cardon LR
    Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214
    [No Abstract]   [Full Text] [Related]  

  • 16. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Market watch: Upcoming market catalysts in Q3 2016.
    Ranj T
    Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354
    [No Abstract]   [Full Text] [Related]  

  • 18. The brains behind blockbusters.
    Couzin J
    Science; 2005 Jul; 309(5735):728. PubMed ID: 16051786
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.
    Shih HP; Zhang X; Aronov AM
    Nat Rev Drug Discov; 2018 Jan; 17(1):19-33. PubMed ID: 29075002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutting the cost of drug development?
    Rawlins MD
    Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 34.